| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
in order to assess gh criteria for newly diagnosed acromegaly with a modern assay we have evaluated gh levels in 25 patients referred to our neuroendocrine unit for evaluation of untreated acromegaly. |
2004-07-27 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
most patients presented with classical manifestations of acromegaly, but 3 of the 5 patients with low nadir gh values had only very subtle signs of acromegaly. |
2004-07-27 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
although most newly diagnosed patients have classically elevated gh levels and obvious clinical features of acromegaly, early recognition of disease may uncover patients with milder biochemical and clinical abnormalities. |
2004-07-27 |
2023-08-12 |
human |
| Pamela U Freda, Carlos M Reyes, Abu T Nuruzzaman, Robert E Sundeen, Jeffrey N Bruc. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. vol 6. issue 4. 2004-07-27. PMID:15237928. |
conventional gh criteria for the diagnosis of acromegaly cannot be applied to the use of modern sensitive and specific gh assays. |
2004-07-27 |
2023-08-12 |
human |
| Flavia Lucia Conceição, Sanne Fisker, Marianne Andersen, Andreas Kaal, Jens Otto Lunde Jørgensen, Mario Vaisman, Jens Sandahl Christianse. Evaluation of growth hormone stimulation tests in cured acromegalic patients. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 6. 2004-07-20. PMID:14624769. |
we have evaluated the gh peak response to insulin tolerance test (itt) and to ghrh+arginine in 11 patients cured of acromegaly after treatment with surgery/radiotherapy and compared them to a control group matched for age and sex. |
2004-07-20 |
2023-08-12 |
Not clear |
| S Radian, M Coculescu, J F Morri. Somatotroph to thyrotroph cell transdifferentiation during experimental hypothyroidism - a light and electron-microscopy study. Journal of cellular and molecular medicine. vol 7. issue 3. 2004-07-19. PMID:14594554. |
cells expressing both thyrotropin (tsh) and growth-hormone (gh) are found in adult rat pituitary and in human pituitary adenomas in acromegaly, and these tumors contain both thyrotropin-releasing hormone (trh) and the trh receptors (trhr). |
2004-07-19 |
2023-08-12 |
human |
| Robert D Murray, Kiwon Kim, Song-Guang Ren, Ian Lewis, Gisbert Weckbecker, Christian Bruns, Shlomo Melme. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. The Journal of clinical endocrinology and metabolism. vol 89. issue 6. 2004-07-19. PMID:15181094. |
currently available somatostatin analogs predominantly bind to the somatostatin receptor subtype (sstr)2 subtype, and control gh and igf-i secretion in approximately 65% of patients with acromegaly, their efficacy relating to receptor density and subtype expression. |
2004-07-19 |
2023-08-12 |
human |
| Angela N Paisley, Peter Trainer, William Drak. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert opinion on biological therapy. vol 4. issue 3. 2004-07-13. PMID:15006735. |
pegvisomant is capable of normalising serum insulin-like growth factor-i concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients with active acromegaly, and therapy is associated with a significant improvement in the symptoms and signs of gh excess. |
2004-07-13 |
2023-08-12 |
Not clear |
| Ruth Mangupli, Aponte Lisette, Contreras Ivett, Camperos Paul, Cruz de los Ríos Victoria, Cevallos Jose Lui. Improvement of acromegaly after octreotide LAR treatment. Pituitary. vol 6. issue 1. 2004-07-06. PMID:14674721. |
monthly injections of 20 mg of octreotide lar were effective to reduce gh and igf-1 levels in patients with active acromegaly accompanied by improvement of clinical symptoms and significant tumor size reduction. |
2004-07-06 |
2023-08-12 |
Not clear |
| Sevim Gullu, Hatice Keles, Tuncay Delibasi, Vedia Tonyukuk, Nuri Kamel, Gurbuz Erdoga. Remission criteria for the follow-up of patients with acromegaly. European journal of endocrinology. vol 150. issue 4. 2004-06-18. PMID:15080775. |
the aim was to evaluate the validity of current remission criteria in acromegaly, a random gh level of <2.5 microg/l, a glucose-suppressed gh level of <1 microg/l and a normal igf-i level. |
2004-06-18 |
2023-08-12 |
Not clear |
| S W van Thiel, J A Romijn, N R Biermasz, B E P M Ballieux, M Frölich, J W A Smit, E P M Corssmit, F Roelfsema, A M Pereir. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European journal of endocrinology. vol 150. issue 4. 2004-06-18. PMID:15080778. |
we hypothesized that the ability to suppress growth hormone (gh) secretion in patients with acromegaly would be similar for these depot preparations. |
2004-06-18 |
2023-08-12 |
Not clear |
| A Giustina, F F Casanueva, F Cavagnini, P Chanson, D Clemmons, L A Frohman, R Gaillard, K Ho, P Jaquet, D L Kleinberg, S W J Lamberts, G Lombardi, M Sheppard, C J Strasburger, M L Vance, J A H Wass, S Melme. Diagnosis and treatment of acromegaly complications. Journal of endocrinological investigation. vol 26. issue 12. 2004-06-17. PMID:15055479. |
fifty nine pituitary specialists (endocrinologists, neurosurgeons and cardiologists) assessed the current published literature on acromegaly complications in light of recent advances in maintaining tight therapeutic control of gh hypersecretion. |
2004-06-17 |
2023-08-12 |
Not clear |
| Pamela U Fred. How effective are current therapies for acromegaly? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914744. |
the goals of these therapies for acromegaly are to normalize excessive hormone secretion, thus normalizing serum levels of growth hormone (gh) and of insulin-like growth factors (igf-i), to reduce the clinical signs and symptoms of acromegaly and to reduce tumor size in order to relieve any symptoms due to tumor mass effect. |
2004-05-13 |
2023-08-12 |
Not clear |
| Peter J Traine. Metabolic effects of GH antagonism in patients with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914745. |
metabolic effects of gh antagonism in patients with acromegaly. |
2004-05-13 |
2023-08-12 |
Not clear |
| Peter J Traine. Metabolic effects of GH antagonism in patients with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914745. |
pegvisomant is a growth hormone (gh) receptor antagonist that represents a major advance in the treatment of acromegaly. |
2004-05-13 |
2023-08-12 |
Not clear |
| Ad Rijnberk, Hans S Kooistra, Jan A Mo. Endocrine diseases in dogs and cats: similarities and differences with endocrine diseases in humans. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13 Suppl A. 2004-05-13. PMID:12914747. |
this gh excess originates form the mammary gland and may give rise to acromegaly and insulin resistance. |
2004-05-13 |
2023-08-12 |
human |
| Madhusmita Misra, Karen K Miller, David B Herzog, Kavitha Ramaswamy, Avichal Aggarwal, Cecilia Almazan, Gregory Neubauer, Jeffrey Breu, Anne Klibansk. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. The Journal of clinical endocrinology and metabolism. vol 89. issue 4. 2004-05-11. PMID:15070919. |
the suppression of gh levels after administration of inhibitors of gh secretion such as oral glucose is the definitive test to distinguish normal from pathological states of gh excess, such as acromegaly. |
2004-05-11 |
2023-08-12 |
Not clear |
| J Ayuk, R N Clayton, G Holder, M C Sheppard, P M Stewart, A S Bate. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 89. issue 4. 2004-05-11. PMID:15070920. |
these results confirm the increased mortality in acromegaly and suggest that reduction of gh levels to less than 2 micro g/liter is beneficial in terms of improving long-term outcome. |
2004-05-11 |
2023-08-12 |
human |
| T Sakatani, H Kaji, Y Takahashi, K Iida, Y Okimura, K Chihar. Lactogenic hormone responsive element reporter gene activation assay for human growth hormone. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 5. 2004-05-07. PMID:12932749. |
the serum gh bioactivity (ng/ml) in patients with acromegaly were equal near to their immunoactivity, whereas the bioactivity of the serum gh in a short child with mutant gh (r77c) revealed lower than their immunoactivity. |
2004-05-07 |
2023-08-12 |
human |
| Cheryl A Picket. Diagnosis and management of pituitary tumors: recent advances. Primary care. vol 30. issue 4. 2004-04-22. PMID:15024895. |
although somewhat unclear at this time, gh antagonists hold promise for alternative or adjunct therapy for acromegaly. |
2004-04-22 |
2023-08-12 |
Not clear |